Publication Cover
Hemoglobin
international journal for hemoglobin research
Volume 45, 2021 - Issue 2
194
Views
0
CrossRef citations to date
0
Altmetric
Short Communications

First Report of Compound Heterozygosity for Hb S (HBB: c.20A>T) and Hb Haringey (HBB: c.131A>G)

ORCID Icon, , , &
Pages 136-139 | Received 04 Feb 2021, Accepted 28 Apr 2021, Published online: 16 Jun 2021
 

Abstract

Sickle cell disease variants include hemoglobinopathies that result from inheritance of the sickle cell globin mutation with another globin mutation. The most common variants include the homozygous disease state (Hb SS disease), Hb S (HBB: c.20A>T)/Hb C (HBB: c.19G>A) disease and Hb S/β-thalassemia (Hb S/β-thal). Other rare/less common variants such as Hb S/Hb E (HBB: c.79G>A) and Hb S/HPFH [hereditary persistence of fetal hemoglobin (Hb)] disease exist. We report the first case of compound heterozygosity for Hb S and Hb Haringey (HBB: c.131A>G) in a 35-year-old male following a positive sickle screen test on hospital admission for pancreatitis. Ion exchange high performance liquid chromatography (HPLC), Hb electrophoresis and genetic sequencing were utilized to identify a new sickle Hb variant: Hb S/Hb Haringey. Hb S/Hb Haringey is a newly discovered sickle cell variant which seems to portray a mild/benign clinical phenotype of sickle cell disease.

Acknowledgments

A submitted abstract of this study was accepted and presented as a poster on 10/12/18 at the 46th Annual Convention of the Sickle Cell Disease Association of America (SCDAA), Baltimore, MD, USA. Author's contributions. Concept and design: U.O. Ogu, C.P. Minniti and M.R. Gil; acquisition, analysis, or interpretation of data: U.O. Ogu, C.P. Minniti, M.R. Gil, S.S. Tolu and S.A. Acharya; drafting of the manuscript: U.O. Ogu; critical revision of the manuscript for important intellectual content: U.O. Ogu, C.P. Minniti, M.R. Gil and S.A. Acharya.

Disclosure statement

C.P. Minniti reports consulting with Novartis (Cambridge, MA), Global Blood Therapeutics (South San Francisco, CA), Emmaus Life Science (Torrrance, CA), CSL Behring, (King of Prussia, PA), Roche Diagnostics, (Indianapolis, IN). U.O. Ogu reports consulting with Vertex Pharmaceuticals (Boston, MA), Novo-Nordisk, (Plainsboro, NJ).

Data availability statement

No new data generated.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.